Climb Bio Inc
CLYM2.310USD
+0.070+3.12%
終値 09/19, 16:00（ET）15分遅れの株価
156.54M時価総額
損失額直近12ヶ月PER
詳細情報 Climb Bio Inc 企業名
Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
企業情報
企業コードCLYM
会社名Climb Bio Inc
上場日Aug 10, 2021
最高経営責任者「CEO」Dr. Aoife M. Brennan
従業員数17
証券種類Ordinary Share
決算期末Aug 10
本社所在地20 William Street
都市WELLESLEY HILLS
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号02481
電話番号18668572596
ウェブサイトhttps://climbbio.com/
企業コードCLYM
上場日Aug 10, 2021
最高経営責任者「CEO」Dr. Aoife M. Brennan
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Aug 19
更新時刻: Tue, Aug 19
株主統計
種類
株主統計
株主統計
比率
RA Capital Management, LP
46.37%
Pontifax Venture Capital
7.68%
Access Industries, Inc.
7.39%
Cantor Fitzgerald, L.P
3.69%
Citi Investment Research (US)
2.38%
他の
32.49%
株主統計
株主統計
比率
RA Capital Management, LP
46.37%
Pontifax Venture Capital
7.68%
Access Industries, Inc.
7.39%
Cantor Fitzgerald, L.P
3.69%
Citi Investment Research (US)
2.38%
他の
32.49%
種類
株主統計
比率
Venture Capital
54.05%
Hedge Fund
12.08%
Investment Advisor
11.12%
Corporation
7.39%
Research Firm
3.35%
Investment Advisor/Hedge Fund
1.18%
Individual Investor
0.81%
他の
10.02%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
169
62.56M
92.58%
-4.83M
2025Q1
169
68.90M
101.99%
-1.34M
2024Q4
155
67.64M
100.63%
-51.77K
2024Q3
127
63.79M
95.46%
+1.90M
2024Q2
91
59.36M
99.92%
+31.16M
2024Q1
87
26.17M
94.38%
-3.33M
2023Q4
91
26.16M
95.54%
-3.35M
2023Q3
92
25.94M
95.83%
-3.54M
2023Q2
93
25.92M
96.06%
-3.17M
2023Q1
92
25.90M
96.01%
-3.10M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
RA Capital Management, LP
31.42M
46.49%
--
--
Mar 31, 2025
Pontifax Venture Capital
5.21M
7.7%
+5.21M
--
Mar 31, 2025
Access Industries, Inc.
5.01M
7.41%
--
--
Aug 14, 2024
Cantor Fitzgerald, L.P
2.00M
2.96%
+1.35M
+207.37%
Mar 31, 2025
Citi Investment Research (US)
1.85M
2.74%
+1.83M
+8039.18%
Mar 31, 2025
Affinity Asset Advisors LLC
1.50M
2.22%
+1.00M
+200.00%
Mar 31, 2025
The Vanguard Group, Inc.
1.50M
2.22%
-3.70K
-0.25%
Mar 31, 2025
Deep Track Capital LP
1.04M
1.54%
--
--
Mar 31, 2025
Kynam Capital Management LP
1.05M
1.55%
+500.00K
+91.41%
Mar 31, 2025
Tang Capital Management, LLC
1.00M
1.48%
+1.00M
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Wed, Aug 6
更新時刻: Wed, Aug 6
銘柄名
比率
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
詳細を見る
ProShares Ultra Nasdaq Biotechnology
比率0.01%
iShares Biotechnology ETF
比率0.01%
Invesco Nasdaq Biotechnology ETF
比率0.01%
iShares Micro-Cap ETF
比率0.01%
Avantis US Small Cap Equity ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%
Proshares Ultra Russell 2000
比率0%
ProShares UltraPro Russell2000
比率0%
iShares Neuroscience and Healthcare ETF
比率0%
iShares Russell 2000 Value ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
